|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1299 Pennsylvania Avenue, NW |
Address2 | Suite 825 |
City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 48736-12
|
||||||||
|
6. House ID# 345580000
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Terri Stewart, Senior Vice President, Head of Global Healthcare Government & Public Affairs |
Date | 4/22/2024 6:16:19 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 547: Better Care Better Jobs Act; all provisions of the bill
H.R. 830: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill
H.R. 2534: Preserving Rules Ordered for The Entities Covered Through 340B Act of 2023(PROTECT 340B Act); all provisions of the bill
H.R. 2880: Protecting Patients Against PBM Abuses Act; all provisions of the bill
H.R. 5378: Lower Costs, More Transparency Act; all provisions of the bill
H.R. 7635: The 340B PATIENTS Act of 2024; all provisions of the bill
S. 100: Better Care Better Jobs Act; all provisions of the bill
S. 1339: Pharmacy Benefit Manager Reform Act; all provisions of the bill
S. 1375: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill
S. 1542: Delinking Revenue from Unfair Gouging (DRUG) Act; all provisions of the bill
S. 1967: Patients Before Middlemen (PBM) Act; all provisions of the bill
P.L. 117-169: Inflation Reduction Act of 2022; implementation of Drug pricing provisions
General discussions related to 340B Drug Pricing Program policy issues
General discussions related to Pharmacy Benefit Manager policy issues
General discussions related to Healthcare supply chain policy issues
General discussions related to Drug cost and pricing policy issues
General discussions related to caregiving support and awareness policy issues
General discussions related to the Cancer Moonshot Initiative and the Advanced Research Projects Agency for Health (ARPA-H)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Terri |
Stewart |
|
|
|
Thomas |
Borck |
|
|
|
Mallori |
Merandino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 2880: Protecting Patients Against PBM Abuses Act; all provisions of the bill
H.R. 5378: Lower Costs, More Transparency Act; all provisions of the bill
H.R. 7635: The 340B PATIENTS Act of 2024; all provisions of the bill
S. 1967: Patients Before Middlemen (PBM) Act; all provisions of the bill
P.L. 117-169: Inflation Reduction Act of 2022; implementation of Parts B & D provisions
General discussions related to Drug cost and pricing policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Terri |
Stewart |
|
|
|
Thomas |
Borck |
|
|
|
Mallori |
Merandino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 830: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill
H.R. 5378: Lower Costs, More Transparency Act; all provisions of the bill
H.R. 7635: The 340B PATIENTS Act of 2024; all provisions of the bill
S. 1339: Pharmacy Benefit Manager Reform Act; all provisions of the bill
S. 1375: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill
S. 1542: Delinking Revenue from Unfair Gouging (DRUG) Act; all provisions of the bill
General discussions related to Drug cost and pricing policy issues
General discussions related to Healthcare supply chain policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Terri |
Stewart |
|
|
|
Thomas |
Borck |
|
|
|
Mallori |
Merandino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 2673: American Innovation and R&D Competitiveness Act of 2023; provisions related to Research & Development (R & D) Tax Amortization
S. 866: American Innovation and Jobs Act; provisions related to Research & Development (R & D) Tax Amortization
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
|
David |
Nichols |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S.2127: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024; provisions related to Veteran infertility benefits
P.L. 118-42 (H.R. 4366): Consolidated Appropriations Act, 2024; provisions related to Veteran infertility benefits in the the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Terri |
Stewart |
|
|
|
Thomas |
Borck |
|
|
|
Mallori |
Merandino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
P.L. 117-167: Supreme Court Security Funding Act of 2022 (H.R. 4346 -CHIPS and Science Act of 2022): issues related to the Notice Of Funding Opportunities (NOFO) for Research & Development (R & D)
17. House(s) of Congress and Federal agencies Check if None
Commerce - Dept of (DOC), Natl Institute of Standards & Technology (NIST)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
|
David |
Nichols |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
P.L. 118-42 (H.R. 4366): Consolidated Appropriations Act, 2024; provisions related to Veteran infertility benefits in the the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024
S.2127: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024; provisions related to Veteran infertility benefits
General discussions regarding Veteran access to infertility care
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Terri |
Stewart |
|
|
|
Thomas |
Borck |
|
|
|
Mallori |
Merandino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3136: National Critical Capabilities Defense Act of 2023; provisions related to China and outbound investment review mechanism
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
|
David |
Nichols |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
Discussions related to the Toxic Substances Control Act, PFAS, and the semiconductor industry
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
|
David |
Nichols |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOR
16. Specific lobbying issues
Discussions related to United States - China relations, and export controls
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
|
David |
Nichols |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
P.L. 118-31 (H.R. 2760): National Defense Authorization Act for Fiscal Year 2024; provisions related to the BIOSECURE Act
S. 2226: National Defense Authorization Act for Fiscal Year 2024; provisions related to the BIOSECURE Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Borck |
|
|
|
Mallori |
Merandino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
General discussions related to Biopharmaceutical innovation and patent policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Terri |
Stewart |
|
|
|
Thomas |
Borck |
|
|
|
Mallori |
Merandino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |